Skip Navigation

European Heart Journal 2002 23(20):1625-1631; doi:10.1053/euhj.2002.3328
Copyright © 2002 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (20)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Maisch, B.
Right arrow Articles by Moll, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Maisch, B.
Right arrow Articles by Moll, R.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Neoplastic pericardial effusion. Efficacy and safety of intrapericardial treatment with cisplatin

B. Maischa,f1, A.D. Ristica, S. Pankuweita, A. Neubauerb and MollR. c

a Department of Internal Medicine–Cardiology, Philipps University, Marburg, Germany
b Department of Internal Medicine–Haematology/Oncology, Philipps University, Marburg, Germany
c Department of Pathology, Philipps University, Marburg, Germany

revised June 11, 2002; accepted June 12, 2002

Abstract

Aims To evaluate the clinical efficacy, safety, and long-term effect of intrapericardial treatment with cisplatin in large neoplastic pericardial effusions.

Methods and Results Out of the registry of 260 patients undergoing pericardiocentesis, 42 patients with neoplastic pericardial effusion (69% males, mean age 58.8±13·2 years) were selected for treatment with cisplatin (single instillation of 30mg.m–2.24h–1) in addition to the tumour-specific systemic chemotherapy. All patients underwent clinical examination, echocardiography, pericardiocentesis, pericardioscopy, and epicardial biopsy. Pericardial effusion and biopsy analyses included biochemistry, cytology, serology, microbiology, histology, immunohistology, and PCR. The following malignancies were established: lung cancer, 52·4%; breast cancer, 19·0%; Hodgkin's disease, 4·8%; oesophageal cancer, 2·4%; mesothelioma, 2·4%; colon cancer, 4·8%; and undifferentiated cancer of unknown origin, 14·2%. Cisplatin appeared to prevent recurrence of pericardial effusion during the first 3 months of the follow-up in 92·8%, and after 6 months in 83·3% of the patients. Lung cancer patients had fewer effusion relapses at the 6 months follow-up (4·5%) than breast cancer patients (37·5%)(P<0·05). Myocardial ischemia occurred after 1/42 cisplatin instillations, but there were no other complications.

Conclusion Intrapericardial treatment with cisplatin appeared to successfully prevent recurrences of neoplastic pericardial effusion. The treatment was more successful in lung than in breast cancer patients.Copyright 2002 The European Society of Cardiology. Published by Elsevier Science Ltd. All rights reserved .

Key Words: Cisplatin, pericardium, pericarditis, pericardial effusion, tumours

f1 Correspondence: Prof. Dr Bernhard Maisch, FESC, FACC, Director, Dept. of Internal Medicine-Cardiology, Philipps University, Marburg, Baldingerstrasse 1, 35033 Marburg, Germany.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
B. P.H. Wittgen, P. W.A. Kunst, K. van der Born, A. W. van Wijk, W. Perkins, F. G. Pilkiewicz, R. Perez-Soler, S. Nicholson, G. J. Peters, and P. E. Postmus
Phase I Study of Aerosolized SLIT Cisplatin in the Treatment of Patients with Carcinoma of the Lung
Clin. Cancer Res., April 15, 2007; 13(8): 2414 - 2421.
[Abstract] [Full Text] [PDF]


Home page
Ann. Surg. Oncol.Home page
J. L. Gross, R. N. Younes, D. Deheinzelin, A. L. Diniz, R. A. da Silva, and F. J. Haddad
Surgical Management of Symptomatic Pericardial Effusion in Patients with Solid Malignancies
Ann. Surg. Oncol., December 1, 2006; 13(12): 1732 - 1738.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
P.-Y. Levy, P.-E. Fournier, R. Charrel, D. Metras, G. Habib, and D. Raoult
Molecular analysis of pericardial fluid: a 7-year experience
Eur. Heart J., August 2, 2006; 27(16): 1942 - 1946.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
N Becit, Y Unlu, M Ceviz, C U Kocogullari, H Kocak, and Y Gurlertop
Subxiphoid pericardiostomy in the management of pericardial effusions: case series analysis of 368 patients
Heart, June 1, 2005; 91(6): 785 - 790.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
B. Maisch
Recurrent pericarditis: mysterious or not so mysterious?
Eur. Heart J., April 1, 2005; 26(7): 631 - 633.
[Full Text] [PDF]


Home page
Jpn J Clin OncolHome page
K. Kaira, A. Takise, G. Kobayashi, M. Utsugi, T. Horie, T. Mori, H. Imai, M. Inazawa, and M. Mori
Management of Malignant Pericardial Effusion with Instillation of Mitomycin C in Non-small Cell Lung Cancer
Jpn. J. Clin. Oncol., February 1, 2005; 35(2): 57 - 60.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
Task Force members, B. Maisch, P. M. Seferovic, A. D. Ristic, R. Erbel, R. Rienmuller, Y. Adler, W. Z. Tomkowski, G. Thiene, M. H. Yacoub, et al.
Guidelines on the Diagnosis and Management of Pericardial Diseases Executive Summary: The Task Force on the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology
Eur. Heart J., April 1, 2004; 25(7): 587 - 610.
[Full Text] [PDF]


Home page
Ann OncolHome page
K. Reynen, U. Kockeritz, and R. H. Strasser
Metastases to the heart
Ann. Onc., March 1, 2004; 15(3): 375 - 381.
[Full Text] [PDF]


Home page
HeartHome page
B. Maisch and A. D Ristic
Practical aspects of the management of pericardial disease
Heart, September 1, 2003; 89(9): 1096 - 1103.
[Full Text] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.